Nabriva Therapeutics (NASDAQ:NBRV) Posts Earnings Results, Misses Expectations By $0.01 EPS

Nabriva Therapeutics (NASDAQ:NBRVGet Rating) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01), MarketWatch Earnings reports. Nabriva Therapeutics had a negative return on equity of 82.13% and a negative net margin of 171.14%. During the same period in the prior year, the firm earned ($0.53) earnings per share.

NBRV stock traded down $0.03 during midday trading on Friday, hitting $0.26. The company’s stock had a trading volume of 958,448 shares, compared to its average volume of 456,432. The company has a market cap of $157.30 million, a PE ratio of -0.28 and a beta of 1.57. Nabriva Therapeutics has a 12 month low of $0.26 and a 12 month high of $2.32. The company has a current ratio of 3.59, a quick ratio of 2.94 and a debt-to-equity ratio of 0.08. The firm’s 50-day moving average is $0.39 and its 200-day moving average is $0.61.

A number of institutional investors and hedge funds have recently made changes to their positions in NBRV. Millennium Management LLC purchased a new stake in Nabriva Therapeutics during the 2nd quarter valued at $42,000. Geode Capital Management LLC raised its stake in Nabriva Therapeutics by 102.9% during the 3rd quarter. Geode Capital Management LLC now owns 42,738 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 21,672 shares during the last quarter. Virtu Financial LLC purchased a new stake in Nabriva Therapeutics during the 4th quarter valued at $125,000. Morgan Stanley raised its stake in Nabriva Therapeutics by 832.2% during the 2nd quarter. Morgan Stanley now owns 91,939 shares of the biotechnology company’s stock valued at $125,000 after buying an additional 82,076 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Nabriva Therapeutics by 116.3% during the 4th quarter. Renaissance Technologies LLC now owns 471,300 shares of the biotechnology company’s stock valued at $282,000 after buying an additional 253,415 shares during the last quarter. Institutional investors and hedge funds own 1.55% of the company’s stock.

Several equities analysts recently issued reports on the company. Zacks Investment Research cut Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, April 5th. Northland Securities lowered their price objective on Nabriva Therapeutics from $4.00 to $2.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 30th. Finally, StockNews.com assumed coverage on Nabriva Therapeutics in a research report on Friday. They issued a “hold” rating on the stock.

About Nabriva Therapeutics (Get Rating)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.

See Also

Earnings History for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.